Zibb.com: Alcon Incorporated (Industry News & Blogs)

Alcon Up 47.1% Since SmarTrend's Buy Recommendation - Zibb.com

Wed, 25 Nov 2009 02:21:21 GMT

SmarTrend, our proprietary pattern recognition system, called an Uptrend for Alcon (NYSE:ACL) on May 18, 2009 at $100.72. Since then, Alcon has returned 47.1% as of today's recent price of $148.16. Want to profit from these alerts? Go to www.mysmartrend.com now for a FREE two-week trial. Write to

NovaBay Pharmaceuticals Reports Third Quarter Financials and Prov...

Fri, 13 Nov 2009 14:00:00 GMT

EMERYVILLE, CA--(Marketwire - 11/13/09) - NovaBay Pharmaceuticals, Inc. (AMEX:NBY - News), a clinical-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a

Greenfield to helm ‘Something’

Wed, 11 Nov 2009 21:34:13 GMT

Luke Greenfield (The Girl Next Door) has fallen for Something Borrowed and will direct the romance, produced by Alcon Entertainment toppers Andrew Kosove and Broderick Johnson along with Hilary Swank and Molly Smith through their 2S Films banner..Film News, news from the entertainment source:

Alcon Inc Q3 2009 Earnings Conference Call

Wed, 28 Oct 2009 23:05:21 GMT

Alcon Inc (ACL)Q3 2009 Earnings Call October 28, 2009 8:30 a.m. ETComplete

Earnings roundup: CommVault, Alcon

Wed, 28 Oct 2009 22:31:21 GMT

Among the earnings stories for Wednesday, Oct. 28, from AP Financial News: OCEANPORT, N.J. (AP) _ CommVault Systems Inc. reported a flat fiscal second-quarter profit as rising operating expenses and revenue costs overshadowed an increase in sales. NEW YORK (...

Alcon 3Q profit down 18 percent without tax gain (AP)

Wed, 28 Oct 2009 20:04:09 GMT

Eye drug maker Alcon Inc. said Wednesday its profit fell 18 percent in the third quarter compared with a year ago, when it received a large tax benefit.

BUY OR SELL-Has Nestle got further to run on Alcon sale hopes? (a...

Wed, 28 Oct 2009 10:26:40 GMT

* Recent broker upgrades drive stock rally * Alcon sale could prompt further buybacks * More buybacks priced in? M&A seen as risk By Emma Thomasson ZURICH, Oct 28 (Reuters) - Shares in

Potentia Pharmaceuticals Enters into Licensing and Purchase Optio...

Mon, 26 Oct 2009 11:46:33 GMT

Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory

Potentia reaches deal to license drug to Alcon

Fri, 23 Oct 2009 15:00:26 GMT

Potentia is one of several companies involved in the University of Louisville’s Nucleus: Kentucky’s Life Sciences and Innovation Center LLC. Nucleus provides laboratory and office space for Potentia in its downtown Louisville life-sciences campus.

Potentia Pharmaceuticals, Inc. Enters into Licensing and Purchase...

Fri, 23 Oct 2009 12:00:00 GMT

LOUISVILLE, Ky., Oct. 23 /PRNewswire/ -- Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd.

Alcon Takes On Potentia’s AMD Therapy and Gains Option Related to...

Fri, 23 Oct 2009 00:00:00 GMT

Alcon inked license and purchase option agreements with Potentia Pharmaceuticals for its Phase I treatment for age-related macular degeneration (AMD). For an up-front payment Alcon

'Speed Boyz' swerves toward Alcon

Wed, 14 Oct 2009 15:00:00 GMT

Michael Schiffer has sold his pitch "Speed Boyz" to Alcon Entertainment, and it concerns real-life engineer-turned-teacher Simon Hauger.

Antoine Fuqua in talks to board Prisoners for Alcon, Warner Bros

Wed, 30 Sep 2009 03:54:00 GMT

Antoine Fuqua is in final negotiations to direct Warner Bros-based Alcon Entertainment’s kidnapping thriller Prisoners based on a screenplay by newcomer Aaron Guzikowski.

Alcon To Acquire ESBATech

Tue, 15 Sep 2009 15:28:00 GMT

Alcon has entered into a definitive agreement to acquire ESBATech AG for $150 million in cash at closing, plus achievement-based R&D payments of as much as $439 million.

Alcon To Pay $589 Million For ESBATech

Mon, 14 Sep 2009 19:54:11 GMT

Eye-drug maker Alcon said Monday it will buy Swiss biotechnology company ESBATech AG in a deal worth up to $589 million.

Alcon to buy Swiss biotech firm EsbaTech - MarketWatch

Mon, 14 Sep 2009 05:40:17 GMT

TEL AVIV (MarketWatch) -- Alcon, the Huenenberg, Switzerland, eye-care-products specialist, definitively agreed to acquire EsbaTech AG, the closely held Zürich clinical-stage biotech company, for $150 million cash plus as much as $439 million of additional payments based on milestones. EsbaTech is

Alcon To Buy Swiss Biotech Firm EsbaTech

Mon, 14 Sep 2009 05:39:00 GMT

Alcon To Buy Swiss Biotech Firm EsbaTech

Alcon To Acquire ESBATech - Pharmaceutical Business Review

Sun, 13 Sep 2009 00:00:00 GMT

Alcon has entered into an agreement to acquire ESBATech. Alcon will pay ESBATech shareholders $150m in cash at closing, plus contingent payments of up to $439m based upon the achievement of future research and development milestones.

Alcon "neutral," target price raised

Wed, 15 Jul 2009 17:08:06 GMT

NEW YORK, July 15 (newratings.com) - Analysts at Credit Suisse reiterate their "neutral" rating on Alcon (ticker: ACL). The target price has been raised from $95 to $125. [more]

Bore gauge system measures brake caliper grooves

Mon, 06 Jul 2009 08:00:00 GMT

Bowers Metrology UK has supplied a custom-built bore gauge system to Alcon Components in order to accurately measure internal brake caliper grooves.

Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for V...

Sun, 05 Jul 2009 23:54:53 GMT

LifeSciencesWorld is your online resource for biotechnology, pharmaceutical, medical devices and life sciences industries.

Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for V...

Sun, 05 Jul 2009 22:00:19 GMT

EMERYVILLE, Calif. and HUENENBERG, Switzerland, July 5 -- Alcon, Inc. (NYSE: ACL) and its partner, NovaBay Pharmaceuticals, Inc. (NYSE-AMEX: NBY), announced today that Alcon has begun treating patients in a Phase 2 ...

Alcon Deal Puts Novartis in a Bind

Mon, 15 Jun 2009 01:57:25 GMT

Novartis's pending purchase of Alcon is appearing increasingly costly, cramping its ability to make further acquisitions.

Alcon to extend eye drop product lines

Tue, 26 May 2009 13:20:00 GMT

Alcon recently announced that it is releasing two new line extensions this summer across its Systane Lubricant Eye Drops product line.

Alcon breaks ground for first Asian pharma factory

Mon, 25 May 2009 05:00:00 GMT

Alcon, the world’s largest manufacturer of eye care products, marked the commencement of construction of its first pharmaceutical manufacturing plant in the Asian region on May 25 with a